Showing results (251-260 of 259) with videos related to

Sort By:
Pageof 26
You have reached the last page of results.This site can display upto 259 results.
Blood|February 11, 2026
Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemiaHao Sun, Romanos Sklavenitis Pistofidis, Shirong Liu, et al.
The Journal of Clinical Investigation|December 9, 2021
Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphomaShuhua Yi, Yuting Yan, Meiling Jin, et al.
Cell Research|November 18, 2017
Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemiaLiang Huang, Dan Liu, Na Wang, et al.
Frontiers in Oncology|November 22, 2021
A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in ChinaWeiping Liu, Donglu Zhao, Ting Liu, et al.
Blood|November 19, 2017
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myelomaThierry Facon, Meletios A Dimopoulos, Angela Dispenzieri, et al.
Signal Transduction and Targeted Therapy|July 5, 2026
Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trialFei Li, Keshu Zhou, Wei Xu, et al.
The Lancet. Oncology|September 23, 2014
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trialJesús F San-Miguel, Vânia T M Hungria, Sung-Soo Yoon, et al.
Journal of Hematology & Oncology|March 17, 2017
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in ChinaYuankai Shi, Bo Jia, Wei Xu, et al.
Advances in Therapy|March 22, 2021
Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 TrialYuqin Song, Hui Zhou, Huilai Zhang, et al.
Pageof 26